Skip to content

Journal · Oncology · Updated 15 November 2026

JAMA Oncology

Read JAMA Oncology research on DeepDyve. No university library needed.

JAMA Oncology, published by the American Medical Association, has covered cancer research since 2015. Its papers include clinical trials, cohort studies, meta-analyses and reviews on the treatment of lung, breast, prostate and other cancers, from immunotherapy and radiotherapy to biomarkers such as circulating tumor DNA. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including the American Medical Association.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

JAMA Oncology at a glance

Full title
JAMA Oncology
Abbreviation (NLM)
JAMA Oncol
Publisher
American Medical Association
Print ISSN
2374-2437
Online ISSN (eISSN)
2374-2445
First published
2015
Subjects
Neoplasms
Access model
Subscription
On DeepDyve
Research articles; availability varies by article

Ways to access JAMA Oncology

JAMA Oncology is a subscription journal. To read its articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. The authors’ accepted manuscript. JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository.
  2. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  3. A library. Your university, hospital or public library may subscribe to JAMA Oncology. Check its journal list and whether it offers remote access.
  4. DeepDyve. Read JAMA Oncology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: AMA on JAMA Network’s manuscript policy; NIH Public Access Policy.

Recent JAMA Oncology research worth reading

Published May to July 2026. Summaries describe what the authors report.

  1. LitStreamOncology · Lung cancer

    PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression

    In a meta-analysis of 24 randomized clinical trials with 5546 patients with advanced non-small cell lung cancer and PD-L1 expression of 50% or higher, the authors found chemoimmunotherapy was associated with significantly longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy.

    Di Federico et al. · JAMA Oncology, published online July 1, 2026 · DOI 10.1001/jamaoncol.2026.1548

  2. LitStreamOncology · Lung cancer

    Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults

    In a cohort study of more than 250,000 older patients with metastatic non-small cell lung cancer from 2006 through 2021, the authors report that only 46.8% ever received systemic therapy, with minimal increase over time, and that referral to an oncologist and low comorbidity burden were among the factors associated with treatment.

    Fox et al. · JAMA Oncology, published online July 1, 2026 · DOI 10.1001/jamaoncol.2026.1080

  3. LitStreamOncology · Breast cancer

    Circulating Tumor DNA in Early Breast Cancer

    This review covers circulating tumor DNA assays for minimal residual disease in early breast cancer, reporting that ctDNA positivity after curative-intent therapy is strongly associated with later distant recurrence, while evidence that ctDNA-guided management improves outcomes remains limited.

    JAMA Oncology, May 2026 · DOI 10.1001/jamaoncol.2026.1465

  4. LitStreamRadiation oncology · Prostate cancer

    Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer

    In a phase 1/2 nonrandomized trial of 45 patients with localized prostate cancer given stereotactic body radiotherapy as a single 19 Gy fraction, the authors report that estimated 3-year biochemical relapse-free survival met the predefined primary end point and that treatment was well tolerated.

    JAMA Oncology, June 2026 · DOI 10.1001/jamaoncol.2026.1886

  5. LitStreamRadiation oncology · Breast cancer

    Cardiac Risk After Heart-Sparing Breast Radiotherapy

    In a cross-sectional study of 4908 patients with breast cancer, 2223 of them left-sided, treated with heart-sparing radiotherapy, the authors found that a higher maximum dose to the left anterior descending coronary artery was independently associated with cardiac events, whereas whole-heart dose was not.

    JAMA Oncology, July 2026 · DOI 10.1001/jamaoncol.2026.2066

See every JAMA Oncology article on DeepDyve

Questions about JAMA Oncology

How can I read JAMA Oncology articles without a subscription?

JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository. Your library may also subscribe. DeepDyve lets you read JAMA Oncology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for JAMA Oncology?

JAMA Oncology’s NLM (PubMed) abbreviation is JAMA Oncol.

What is the ISSN of JAMA Oncology?

The print ISSN is 2374-2437 and the online ISSN is 2374-2445.

Is JAMA Oncology open access?

JAMA Oncology articles are published under the subscription model; none of the 339 articles it published from January 1 to November 14, 2026 carry a Creative Commons license in Crossref.

JAMA Oncology articles on DeepDyve are licensed from the American Medical Association. Journal facts as of 15 November 2026.

Start reading JAMA Oncology today

One month free, then less than $2 a day. JAMA Oncology, plus millions of articles from thousands of journals.

Start free month

Like this: